Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
242 hedge funds and large institutions have $4.6B invested in Acceleron Pharma in 2020 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 90 increasing their positions, 67 reducing their positions, and 27 closing their positions.
96% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 27
34% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 67
14% more call options, than puts
Call options by funds: $58.6M | Put options by funds: $51.5M
12% more funds holding
Funds holding: 217 → 242 (+25)
6% more capital invested
Capital invested by funds: $4.32B → $4.6B (+$276M)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$62.1M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$28.3M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$26.9M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$25M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$65.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$46M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$38.1M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$33.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$33.5M |
XLRN Hedge Fund Activity: Q2 2020 in Review
242 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2020, worth a combined $4.6B — up 6.4% from $4.32B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new XLRN positions and 27 closed out — a net gain of 26 holders — while 90 added to existing stakes and 67 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $62.1M. The largest seller was BlackRock, cutting an estimated $65.8M.
- 242 institutional investors held Acceleron Pharma (XLRN) as of Q2 2020, up from 217 in Q1 2020.
- Funds reported $4.6B of Acceleron Pharma stock for Q2 2020, up 6.4% quarter-over-quarter.
- 53 funds opened new Acceleron Pharma positions in Q2 2020 and 27 closed out, a net change of +26 holders.
- The largest Acceleron Pharma buyer in Q2 2020 was T. Rowe Price Associates, an estimated $62.1M added.
- The largest Acceleron Pharma seller in Q2 2020 was BlackRock, an estimated $65.8M sold.
Based on aggregated 13F filings for Q2 2020.